<p>Tafinlar is a cancer medicine used to treat adults whose cancer cells have a specific genetic mutation (change) called ‘BRAF V600’. It is used for the treatment of:</p><ul><li>melanoma (a skin cancer) that has spread or cannot be removed surgically. Tafinlar is used on its own or in combination with another cancer medicine, trametinib;</li><li>advanced (stage III) melanoma after surgery for it. Tafinlar is used in combination with trametinib;</li><li>advanced non-small cell lung cancer. It is used in combination with trametinib.</li></ul><p>Tafinlar contains the active substance dabrafenib.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p><strong>Melanoma</strong></p> <p>Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).</p> <p><strong>Adjuvant treatment of melanoma</strong></p> <p>Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.</p> <p><strong>Non-small cell lung cancer (NSCLC)</strong></p> <p>Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.</p></div>
Therapeutic Area (MeSH)
ATC Code
L01EC02
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| dabrafenib mesilate | N/A | dabrafenib mesilate |
EMA Name
Tafinlar
Medicine Name
Tafinlar
Aliases
N/ANo risk management plan link.
